Zealand Pharma Enrolls First Participant In Phase 2b ZUPREME-2 Trial Of Petrelintide For Overweight Or Obese Adults With Type 2 Diabetes

Zealand Pharma A/S, a biotech company that develops peptide-based medicines, has started a new clinical trial. The company announced that the first participant has been enrolled in the ZUPREME-2 Phase 2b study. This trial will test the effectiveness and safety of petrelintide, a long-acting amylin analog, given once a week by injection. It will be compared to a placebo in people who are overweight or obese and also have type 2 diabetes. Zealand Pharma's company registration number is 20045078.

David Kendall, MD, Chief Medical Officer at Zealand Pharma, said in a statement, 

“We are excited to announce the initiation of ZUPREME-2, the second Phase 2 trial initiated with petrelintide and an important part of our clinical development plan for establishing petrelintide as a best-in-class alternative to incretin-based therapies and a future foundational therapy for weight management. Amylin agonism has shown great potential to provide clinically meaningful weight loss and may also provide additional improvements in glycemic control in people with overweight or obesity and type 2 diabetes, and we look forward to evaluating the efficacy and safety of petrelintide as a weight loss therapy in this population.”